(Note: IPOScoop has NO CALL on this deal. This is a NASDAQ uplisting. This is NOT an IPO, although the prospectus calls the deal an initial public offering of American Depositary Shares (ADS). Each ADS represents 180 ordinary shares. Bionomics Ltd.’s ordinary shares are listed on the Australian Securities Exchange (“ASX”), under the symbol “BNO.”)

We are a clinical-stage biopharmaceutical company developing novel allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Ion channels serve as important mediators of physiological function in the CNS and the modulation of ion channels influences neurotransmission that leads to downstream signaling in the brain. The α7 nicotinic acetylcholine (“ACh”) receptor (“α7 receptor”) is an ion channel that plays an important role in driving emotional responses and cognitive performance. Utilizing our expertise in ion channel biology and translational medicine, we are developing orally active small molecule negative allosteric modulators (“NAMs”) and positive allosteric modulators (“PAMs”) of the α7 receptor to treat anxiety and stressor-related disorders and cognitive dysfunction, respectively.

We are advancing our lead product candidate, BNC210, an oral proprietary selective NAM of the α7 receptor, for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”). There remains a significant unmet medical need for the over 22 million patients in the United States alone suffering from SAD and PTSD. Current pharmacological treatments include certain antidepressants and benzodiazepines, and there have been no new FDA-approved therapies in these indications in nearly two decades. These existing treatments have multiple shortcomings, such as a slow onset of action of antidepressants, and significant side effects of both classes of drugs. BNC210 has been observed in our clinical trials to have a fast onset of action and clinical activity without the limiting side effects seen with the current standard of care.

We expect to initiate our Phase 2 PREVAIL trial for BNC210 for the acute treatment of SAD by the end of 2021 and currently anticipate reporting topline data by the end of 2022. We have initiated our Phase 2b ATTUNE trial, a randomized, placebo-controlled study to evaluate BNC210 for the treatment of PTSD, and we expect to report topline data in the first half of 2023. Our expertise and approach have been validated through our June 2014 research collaboration and license agreement with Merck Sharp & Dohme Corp., a wholly owned subsidiary of Merck & Co., Inc., for our α7 receptor PAM program, which targets a receptor that has garnered significant attention for treating cognitive deficits. This partnership enables us to maximize the value of our ion channel and chemistry platforms and develop transformative medicines for patients suffering from cognitive disorders such as Alzheimer’s disease.

(Note: Bionomics Ltd. priced its public offering on Dec. 15, 2021, at US$12.35 per ADS – $3.10 below its expected price of US$15.45, which was the as-converted close on Dec. 10, 2021, of its ordinary shares. In this offering, Bionomics priced 1.622 million American Depositary Shares (ADS) – the same number of ADS in the prospectus – to raise $20.03 million. Insiders had indicated an interest in buying up to about $15 million of the ADS in this offering – or up to 75 percent of the deal – at the “IPO” price, the prospectus says. Each ADS represents 180 ordinary shares of Bionomics.)